PMV Pharmaceuticals Announces Participation at the Cowen 41st Annual Health Care Conference
PMV Pharmaceuticals (Nasdaq: PMVP) announced its participation in the Lung Cancer Panel at the Cowen 41st Annual Health Care Conference from March 1-4, 2021.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
PMV Pharmaceuticals (Nasdaq: PMVP) announced its participation in the Lung Cancer Panel at the Cowen 41st Annual Health Care Conference from March 1-4, 2021. David H. Mack, Ph.D., CEO, will speak on March 2 at 11:10 AM. PMV Pharma focuses on developing small molecule, tumor-agnostic therapies targeting p53 mutations, prevalent in about half of all cancers. The company's foundation is rooted in over four decades of p53 biology research by co-founder Dr. Arnold Levine.
Positive
- Participation in a reputable health care conference for visibility and investor engagement.
Negative
- None.
Details
News Market Reaction – PMVP
The recorded move for PMVP in the trading session of this news was -10.19%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CRANBURY, N.J., Feb. 23, 2021 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants, today announced that David H. Mack, Ph.D., President & Chief Executive Officer, will participate in the Lung Cancer Panel at the Cowen 41st Annual Health Care Conference taking place virtually on March 1-4, 2021. The company will also participate in one-on-one investor meetings at the conference.
Panel details:
| Cowen 41st Annual Health Care Conference Lung Cancer Panel | |
| Date: | Tuesday, March 2, 2021 |
| Time: | 11:10am |
About PMV Pharma
PMV Pharma is a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53 mutants. p53 mutations are found in approximately half of all cancers. The field of p53 biology was established by our co-founder Dr. Arnold Levine when he discovered the p53 protein in 1979. Bringing together leaders in the field to utilize over four decades of p53 biology, PMV Pharma combines unique biological understanding with pharmaceutical development focus. PMV Pharma is headquartered in Cranbury, New Jersey. For more information, please visit www.pmvpharma.com.
Contact
For Investors and Media:
Winston Kung
Chief Financial Officer
investors@pmvpharma.com
Source: PMV Pharmaceuticals, Inc.
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.